Medincell News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

12.12.24	Medincell to Join the Euronext SBF 120 Index (Businesswire)
09.12.24	Medincell and AIC Unveil New Positive Phase 3 Results for mdc-CWM: Major Subgroup Analysis Shows Reduced Pain and Opioid Use, and Accelerated Rehabilitation following Total Knee Replacement (Businesswire)
06.11.24	Medincell: 25% Raise in 2024 UZEDY® Revenue Outlook & Key Milestone Reached for Olanzapine LAI Clinical Phase 3 (Businesswire)
04.11.24	Medincell’s Partner Teva Unveils New Phase 3 Positive Results for Olanzapine LAI, and Presents Real-World Data on UZEDY® at Psych Congress 20241 (Businesswire)
23.09.24	Medincell’s Partner Teva Presented New Efficacy, Safety, and Tolerability Data from Pivotal Phase 3 of Olanzapine LAI for Adult Patients Diagnosed with Schizophrenia (Businesswire)
23.09.24	Medincell’s Partner Teva Provided Treatment Insights into Switching to UZEDY® from Perseris® (Businesswire)
05.09.24	Medincell’s Partner Teva Provides New Update on Pivotal Clinical Phase 3 of Investigational Olanzapine Long-Acting Injectable (LAI) (Businesswire)
03.09.24	Medincell Announces Progress in the Development of its Products Portfolio and R&D Pipeline (Businesswire)
31.07.24	Medincell’s partner Teva provides update on pivotal clinical Phase 3 of investigational Olanzapine Long-Acting Injectable (LAI) and UZEDY® commercial progress (Businesswire)
08.05.24	Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia (Businesswire)
16.04.24	Medincell Enters Into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies (Businesswire)
08.04.24	Unitaid Awards Medincell up to $6 million Extension Grant to Fight Malaria (Businesswire)
31.01.24	MedinCell’s Partner Teva Provides Guidance for UZEDY in 2024 and an Update on the Treatment-Candidate of Olanzapine Long-Acting Injectable (LAI) (Businesswire)
09.01.24	MedinCell’s partner Teva Announces Recruitment Completion of Phase 3 Clinical Study of mdc-TJK / Olanzapine Long-Acting Injectable (LAI) (Businesswire)
13.11.23	MedinCell Applauds Teva and Royalty Pharma Collaboration to Further Accelerate Olanzapine LAI Program (Codename: mdc-TJK or TEV-‘749) (Businesswire)
30.08.23	MedinCell announces successful completion of patient enrollment in the Phase 3 study of F14 (mdc-CWM), a first-in-class therapy for localized pain relief after Total Knee Replacement (Businesswire)
04.05.23	MedinCell: mdc-TJK's (Teva's codename: TEV-44749) Phase 1 study pharmacokinetics to be presented for the first time by Teva at SIRS 2023 (May 11-15, 2023, Toronto, Canada) (Businesswire)
24.01.23	Initiation of the Phase 3 study for the second long-acting injectable antipsychotic using MedinCell’s technology (program mdc-TJK) (Businesswire)
05.01.23	MedinCell announces positive results for the SAIVE clinical study in prevention of Covid-19 infection in a contact-based population (Businesswire)
30.11.22	Additional US$ 4 Million Received for Next Development Steps of MedinCell's 6-Month Active Injectable Bioresorbable Subcutaneous Contraceptive (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	952.60	1.88 %	K V
Swiss Re	142.05	1.10 %	K V
Kuehne+Nagel Int	161.15	1.10 %	K V
Lonza Grp	546.80	1.07 %	K V
UBS Group	30.91	0.91 %	K V
Sika	158.05	0.03 %	K V
Alcon	63.94	-0.03 %	K V
Swisscom	583.50	-0.34 %	K V
Novartis	104.64	-0.63 %	K V
Roche Hldg G	309.30	-1.15 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Medincell Aktie VALOR 1633005 / ISIN FR0004065605

Nachrichten zu Medincell SA Reg S

Aktien Top/Flop

Meistgelesene Nachrichten